ClinicalTrials.gg
RecruitingNCT07813637PSMA-013-001Updated Sep 17, 2026

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

A Phase 1 interventional study of JANX013 and JANX007 in Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC) and Metastatic Prostate Cancer, sponsored by Janux Therapeutics. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Janux Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 975 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
859th of 3,023
110 · median 48
Started
2026
with 175 others
Phase 1
615 of 3,596
83 open now
Primary completion
2029-07
later than 810 of 969 live
Registered
3,571st of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 859th largest by planned enrollment of the 3,023 interventional ones that give a count, is one of 176 that started in 2026, is one of 615 in phase 1, reaches primary completion later than 810 of the 969 other live ones, and was the 3,571st registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

03

Conditions studied

  • Prostate Cancer
  • Castration-Resistant Prostate Cancer (CRPC)
  • Metastatic Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer Patients

Browse trials for

Keywords

  • mCRPC
  • Metastatic Castration-Resistant Prostate Cancer
  • PSMA
  • Prostate-Specific Membrane Antigen
  • CD3 T cell engager
  • T cell engager
  • Bispecific antibody
  • Immunotherapy
  • Prostate cancer metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male participants ≥ 18 years of age at the time of signing
  • or cytologically confirmed adenocarcinoma of the prostate

For Dose Escalation:

- Have received at least 1 novel ARPI (e.g., abiraterone acetate, enzalutamide, apalutamide, or darolutamide) in any setting and have received at least 1 taxane regimen (in any setting), or who are medically unsuitable or have actively refused treatment with a taxane regimen.

For Dose Expansion:

  • Must be in the or second-line setting for mCRPC or androgen pathway modulation resistant disease and must have received 1 novel ARPI in any setting.
  • Adequate organ function

Key Exclusion Criteria:

  • Prior treatment with any chimeric antigen receptor (CAR) T-cell therapy, any approved or TCE, or any T-cell costimulatory agent
  • cardiovascular disease
  • Prior solid organ transplant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Participants receive JANX013 in combination with JANX007 administered at increasing dose levels per cohort

    Drug: JANX013 · Drug: JANX007

  • Experimental
    Dose Expansion

    Participants receive JANX013 in combination with JANX007. Participants will be dosed at levels previously declared tolerable.

    Drug: JANX013 · Drug: JANX007

Interventions

  • DrugJANX013

    JANX013 will be administered via IV dosing.

  • DrugJANX007

    JANX007 will be administered via IV dosing.

  • DrugJANX013

    JANX013 will be administered via IV dosing

  • DrugJANX007

    JANX007 will be administered via IV dosing

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

    Time frame: 2 years

  2. Incidence of cytokine release syndrome (CRS)

    Cytokine release syndrome (CRS) assessed according to ASTCT criteria.

    Time frame: 2 years

Secondary outcomes

  1. Area under the curve from 0 to t of JANX013 and JANX007

    Time frame: Up to 2 years

  2. Maximum observed concentration of JANX013 and JANX007

    Time frame: Up to 2 years

  3. Time to maximum concentration of JANX013 and JANX007

    Time frame: Up to 2 years

  4. Number of participants who develop anti-drug antibodies (ADAs) against JANX013 and JANX007

    Time frame: Up to 2 years

  5. Prostate-specific antigen (PSA) response

    Time frame: Up to 2 years

  6. Radiographic progression-free survival (rPFS)

    Time frame: Up to 2 years

  7. Duration of response (DOR)

    Time frame: Up to 2 years

  8. Disease control rate (DCR)

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2029, 34 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 34 months is close to that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 10, 2026
StartActual
Sep 10, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2030
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07813637
Lead sponsor
Janux Therapeutics
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Sep 10, 2026
Primary completion
Jul 2029 (estimated)
Completion
Jul 2030 (estimated)
Last update
Sep 17, 2026

Study contacts

Janux Therapeutics, MD
Contact
PSMA-013-001_ct.gov@januxrx.com
1-858-206-8471

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion